{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-119533","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.645340+00:00","generated_at":"2026-06-21T17:24:06.377630+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Esperion appoints Ben Halladay as CFO, effective Nov 16, 2022","bullets":["Ben Halladay appointed CFO effective Nov 16, 2022; previously Senior Director of FP&A at Esperion.","Annual base salary of $429,000; target annual bonus of 40% of base salary.","Reports to CEO Sheldon Koenig; prior roles at National Oilwell Varco, BMC Software, and Pfizer.","Holds CPA license; BA from Syracuse University and MBA from Fordham Gabelli School of Business."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-119533","json":"https://secwatch.observer/filing/0001104659-22-119533.json","markdown":"https://secwatch.observer/filing/0001104659-22-119533.md","text":"https://secwatch.observer/filing/0001104659-22-119533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922119533/0001104659-22-119533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922119533/tm2230242d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:24:06.377630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1936449ea1","claim":"Benjamin Halladay was appointed as Chief Financial Officer at Esperion Therapeutics, Inc..","evidence_excerpt":"On November 16, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Benjamin Halladay as the Company’s Chief Financial Officer pursuant to the terms of an employment agreement with Mr. Halladay (the “Halladay Agreement”), effective as of November 16, 2022 (the “Commencement Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922119533/0001104659-22-119533-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}